Figure 2

Impact of ANDES virus infection on iDC phenotype and functions. (A) The impact of ANDV infection on DCs viability was detected by using the Annexin V-propidium iodide (PI) method. In these assays, DCs treated with camptothecin A (4 μM for 18 h) were used as a positive apoptosis control. (B) DCs surface markers; CD80, CD86, CD83 and HLA-DR were analyzed in ANDV-infected iDCs by flow cytometry four days post-ANDV infection, while LPS-pulsed DCs and uninfected iDCs (mock) were used as controls. Bar graphs represent the fold-increase expression of these surface markers as compared their expression in mock control. Data are means of three independent experiments: *, p< 0.05; **, p < 0.01. (C) The endocytic capacity of ANDES infected iDCs, LPS-matured DCs (mDC), uninfected iDCs incubated at 37°C (iDC 37), and uninfected iDCs incubated at 4°C (iDC 4) was assessed using a FITC-conjugated Dextran (30 μg). Endocytosis was analyzed by flow cytometry after 2 h of incubation. Mean fluorescence intensity values within the gate for the different endocytically active stages were plotted. Bar graphs show the fold-increases of the mean fluorescence intensities (MFI), relative to the mock control (iDCs 37). For each experiment, 10 000 gated cells were evaluated. Data are means of five independent experiments. *, p< 0.05; **, p < 0.01.